Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.66 |
| ▸ | CES2 | O00748 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP19 | O94966 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526192 | 0.99 | FAAH (0.67) | FAAHCES2NPC1RAB9APKM | |
| SCHEMBL14950286 | 0.90 | FAAH (0.54) | FAAHCES2KMOGRIN2BGRM5 | |
| SCHEMBL427830 | 0.88 | FAAH (0.66) | FAAHCES2NPC1RAB9APOLB | |
| SCHEMBL14950186 | 0.88 | FAAH (0.64) | FAAHCES2NPC1RAB9APOLB | |
| SCHEMBL424383 | 0.88 | FAAH (0.74) | FAAHCES2NPC1RAB9APOLB | |
| SCHEMBL15554007 | 0.87 | FAAH (0.64) | FAAHCES2NPC1RAB9APOLB | |
| SCHEMBL424585 | 0.87 | FAAH (0.67) | FAAHCES2NPC1RAB9APOLB | |
| SCHEMBL425372 | 0.87 | FAAH (0.67) | FAAHCES2NPC1RAB9APOLB | |
| SCHEMBL14950257 | 0.87 | FAAH (0.52) | FAAHCES2KMT2AUSP19GRIN2B | |
| SCHEMBL14950289 | 0.87 | FAAH (0.66) | FAAHCES2NPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | UTS2R, ARG1, PRMT1 | FAAH 2166/4885CES2 463/4885NPC1 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.